The global schizophrenia drugs market is experiencing sustained growth, driven by a combination of increased mental health awareness, pharmaceutical breakthroughs, and rising disease prevalence. Valued at USD 8.36 billion in 2024, the market is projected to reach USD 12.78 billion by 2032, expanding at a CAGR of 5.46% over the forecast period from 2025 to 2032. With over 24 million people...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek